The Aenova Group, one of the leading companies in the global pharmaceutical and health care industry, is succeeding in integrating the Temmler Group into its organization. With immediate effect, Dr. Werner Schneider becomes a member of the top-level Aenova management team with responsibility for business development, while Matthias Utrata is responsible for tax, treasury and compliance. Both previously worked for the pharmaceutical manufacturing company Temmler, which was taken over by Aenova at the end of 2012.

The appointment of Werner Schneider and Matthias Utrata to the management team will complement its strengths and represents another step towards the successful integration of the Temmler Group. In this context, Aenova CEO Heiner Hoppmann emphasized the positive impact that the new management team members will have on the company.

“We are very pleased that Werner Schneider and Matthias Utrata have joined us. Their many years of experience of the pharmaceutical industry and their competence in this area will enable both of them to make a significant contribution to strengthening the position of the Aenova Group,” said Hoppmann.

Werner Schneider, who has a PhD in biology, has been CEO of the Temmler Group and part of the management team since September 2006. Before this he was a member of the board of Lichtwer Pharma with responsibility for research and development, together with production and technology. Previously he held the role of scientific director and company secretary at Steigerwald Arzneimittelwerk GmbH. As CFO of the Temmler Group, Matthias Utrata was responsible for finance, IT, HR and corporate communication. On Feb. 1, 2013, he was appointed director of tax, treasury and compliance, reporting to Frank Elsen, CFO of the Aenova Group.